Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
This license will enable Abbott to enhance access to this novel therapy to more patients across India
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Subscribe To Our Newsletter & Stay Updated